Zobrazeno 1 - 9
of 9
pro vyhledávání: '"59"'
Publikováno v:
Idiopathic interstitial pneumonias.
Background: Idiopathic pulmonary fibrosis (IPF) is fatal, progressive fibrosing, lung disease of unknown cause. Anti-fibrotic drugs can slow down the progression of the disease and reduce mortality. However, discontinuation rates of 19-21% have been
Autor:
Stefan Fischer, A Akil, Michael Semik, Nicolas Dickgreber, Deborrah Wehde, Mehyar Lavae-Mokhtari
Publikováno v:
Lung cancer.
Introduction: Small cell lung cancer makes up about 15 percent of all lung cancers. Extensive stage small cell lung cancer (ES-SCLC) carries a poor prognosis, and the thoracic progression is common. It is usually an aggressive cancer that tends to gr
Autor:
Elisabetta Caiazzo, Fiorentina Roviezzo, Ida Cerqua, Armando Ialenti, Maria Antonietta Riemma, Carla Cicala
Publikováno v:
Allergy and immunology.
Increasing evidence suggests that extracellular adenosine is an important signaling nucleoside in the pathophysiology of bronchial asthma (1). CD73 is the key enzyme in the extracellular adenosine production (2). To date, very little is known about t
Autor:
Anastasiia Korotkaia, Matthias Griese, Annick Clement, Deborah Snijders, Steve Cunningham, Andrew Bush, Katarzyna Krenke, Nural Kiper, Meike Hengst, Nicolaus Schwerk, Martin Wetzke, Joanna Lange, Julia Carlens, Elias Seidl
Publikováno v:
Diffuse Parenchymal Lung Disease.
Introduction: Children’s interstitial lung disease (chILD) comprises a heterogeneous group of over 200 different entities of diffuse lung diseases with symptom onset in childhood. Only 1-3 of one million children are affected per year. No evidence
Autor:
Michael Kreuter, Andreas Günther, Klaus F. Rabe, Juergen Behr, Carmen Schade-Brittinger, Jasmin Wagner, Antje Prasse, Petra Neuser
Publikováno v:
Clinical Problems Others.
Pirfenidone is approved in the EU for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF), but not for other forms of progressive fibrotic lung diseases, in which anti-inflammatory therapy is not sufficiently effective. RELIEF, a ra
Publikováno v:
1.13 Clinical Problems - Other.
Back ground: To investigate the clinical and radiological characteristics as well as the bronchoscopic appearance in patients with endobronchial aspergilloma (EBA). Methods: We analyzed the clinical and radiological characteristics as well as the bro
Publikováno v:
7.7 Paediatric Bronchology.
Background: Acute onset of barking cough, hoarseness, and stridor are characteristic for viral croup, which has to be differentiated from rare bacterial laryngotracheitis. Aim: To describe clinical features and findings in children with non-viral cro
Autor:
Dora Marinova, Vanyo Mitev, Dimitar Kostadinov, Radka Kaneva, Gergana Stancheva, Darina Kachakova, Yanina Slavova, Atanaska Mitkova
Publikováno v:
11.1 Lung Cancer.
The fusion EML4-ALK oncogene is expressed in about 5-13% of non-small cell lung cancers (NSCLC), mainly in young men, non-smokers with adenocarcinoma. These tumors manifest dramatic response to ALK inhibitors, such as Crizotinib. Accurate identificat
Autor:
Charlie Elliot, Neil Hamilton, Robin Condliffe, Mark Graves, Michaela Sellars, Iain Armstrong, Athanasios Charalampopolous, David G. Kiely
Publikováno v:
4.3 Pulmonary Circulation and Pulmonary Vascular Disease.
Background: The SERAPHIN trial showed Macitentan, a selective Endothelin Receptor Antagonist (ERA) reduced morbidity and mortality in PAH. Aim: To describe early clinical experience with Macitentan in a specialist PH centre. Results: To date, 94 PAH